Impact of Prealbumin Levels on Patients with Acute Kidney Injury

Wenji Wang,Yu Pang,Feng Ding
DOI: https://doi.org/10.1177/0003319715604266
2015-01-01
Angiology
Abstract:We thank Agilli et al for their interest in our article. They claimed that several factors, including diseases, drugs, and even the way samples are collected, can affect prealbumin serum levels. We agree with their comments. Protein energy malnutrition is a chronic and acute lean body protein loss that leads to a state of specific nutrient deficiency and is associated with a worse outcome during illness and may be reversed by conversion to an anabolic state. Serum prealbumin, a nutritional marker with a short half-life and a rapid synthesis rate, was affected by several factors including some diseases, inflammation, malnutrition, some drugs such as prednisone, and alcohol use. Our current study indicated that the incidence of major adverse events (MAEs) significantly increased in patients with lower levels of serum prealbumin. After adjustment for confounders, serum prealbumin levels emerged as one of the significant predictors of MAEs (death from any cause and further deterioration in renal function requiring chronic dialysis) in patients undergoing peripheral arterial angiography. In this cohort study, we excluded patients with multiple myeloma and the use of nonsteroidal anti-inflammatory drugs or corticosteroids. There was no significant difference between patients with and without MAEs in current drinking (P1⁄4 .620). This result was consistent with previous studies which evaluated prealbumin levels in patients after peripheral arterial angiography. Several studies suggested that malnutrition has a negative impact on the prognosis in patients with acute kidney injury (AKI) or heart failure. The meta-analysis provided evidence that hypoalbuminemia is a significant independent predictor of death following AKI development. According to Valdivieso et al, serum prealbumin levels <11 mg/dL were strongly associated with increased in-hospital mortality (hazard ratio, 2.10; 95% confidence interval, 1.08-4.08), compared to patients with the same AKI severity and treatment but with a serum prealbumin level 11 mg/dL. In addition, each increment of 5 mg/dL of serum prealbumin was associated with an adjusted 29% decrease in in-hospital morality. In a heart failure study, patients with discharge prealbumin 15 mg/dL had a higher 6-month morbidity and mortality. Similarly, in our previous study, a lower level of prealbumin was found to be significant in patients with hospital-acquired AKI who died within 28 days compared to those who survived >28 days (12.5 + 5.9 vs 16.4 + 6.9 mg/dL, P 1⁄4 .001). Furthermore, we are conducting another study to assess the impact of serum prealbumin level on prognosis of patients with AKI after coronary artery bypass graft operation. The results also show an independent association between lower prealbumin level and mortality. In conclusion, serum prealbumin could be an independent predictor of MAEs in AKI. Its serum levels should always be interpreted in light of the influencing factors, among which are concomitant disease, the inflammatory state, and liver function.
What problem does this paper attempt to address?